# Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

> **NCT01061749** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Adult Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Cixutumumab
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT01061749
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-04
- **Final completion:** 2014-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061749, "Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT01061749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*